Cost-effectiveness of the once-daily efavirenz/ emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/ tenofovir tablet as frst-line antiretroviral therapy in HIV-infected adults in the US

ClinicoEconomics and Outcomes Research

Volumn 5, Issue 1, 2013, Pages 437-445

  Juday, Timothy ^a   Correll, Todd ^a   Anene, Ayanna ^b   Broder, Michael S ^b   Ortendahl, Jesse ^b   Bentley, Tanya ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b PARTNERSHIP FOR HEALTH ANALYTIC RESEARCH   (United States)

Author keywords

Antiretroviral therapy; Cost effectiveness; Human immunodeficiency virus

Indexed keywords

COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HIDDEN MARKOV MODEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; QUALITY OF LIFE; RASH; SENSITIVITY ANALYSIS; TABLET FORMULATION; UNITED STATES;

EID: 84883650186     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S47486     Document Type: Article

References (34)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Updated February 12, 2013. Available from: http://aidsinfo.nih.gov/contentfles/lvguidelines/adultandadolescentgl.pdf. Appendix B, Table 7, and Table 8. Accessed March 29, 2013.
2. Sax PE, DeJesus E, Mills A, et al; GS-US-236-0102 Study Team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379(9835):2439-2448.
3. National Center for Health Statistics. Table 2. Lifetable for males, 2007-2008. Atlanta, GA: Centers for Disease Control and Prevention; 2012. Available from: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/NVSR/59_09/Table02.xls. Accessed March 29, 2013.
4. Centers for Disease Control and Prevention. HIV Surveillance Report, volume 22, 2010. Available from: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/. Accessed January 11, 2013.
5. Wyatt CM, Arons RR, Klotman PE, Klotman ME. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS. 2006;20(4):561-565.
6. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O'Hare AM. The impact of HIV on chronic kidney disease outcomes. Kidney Int. 2007;72(11):1380-1387.
7. Byakwaga H, Murray JM, Petoumenos K, et al. Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression. AIDS Res Hum Retroviruses. 2009;25(6):756-776.
8. Le Moing V, Thiébaut R, Chêne G, et al; ANRS CO8 (APROCO/ COPILOTE) Study Group. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently,500 copies/mL during treatment with antiretroviral drugs. HIV Med. 2007;8(3): 156-163.
9. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44(3):441-446.
10. Gulick RM, Lalezari J, Goodrich J, et al; MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359(14):1429-1241.
11. Baker J V, Peng G, Rapkin J, et al; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008;22(7):841-848.
12. Bureau of Labor Statistics. Consumer Price Index Inflation Calculator. United States Department of Labor. Available from: http://www.bls.gov/data/infation_calculator.htm. Accessed March 29, 2013.
13. Price Rx. Wolters Kluwer Health 2012. Available from: https://pricerx.medispan.com/NDCNumber.aspx. Accessed September 7, 2012.
14. Candrilli S, Bell T, Irish W, Morris E, Goldman S, Cairo MS. A comparison of inpatient length of stay and costs among patients with hematologic malignancies (excluding Hodgkin disease) associated with and without acute renal failure. Clin Lymphoma Myeloma. 2008;8(1):44-51.
15. Berger A, Edelsberg J, Inglese G W, Bhattacharyya SK, Oster G. Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease. Am J Manag Care. 2009;15(8):509-518.
16. Simpson KN, Luo M P, Chumney E, Sun E, Brun S, Ashraf T. Cost-effectiveness of lopinavir/ritonavir versus nelfnavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials. 2004;5(5):294-304.
17. Grosse SD, Teutsch SM, Haddix AC. Lessons from cost-effectiveness research for United States public health policy. Annu Rev Public Health. 2007;28:365-391.
18. King JT Jr, Tsevat J, Lave JR, Roberts MS. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making. 2005;25(6):667-677.
19. Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518-528.
20. Gilead Sciences Inc. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (EVG/COBI/FTC/TDF, QUAD STR) for treatment of HIV-1 infection in adults. Antiviral Drugs Advisory Committee Meeting Briefng Document. May 11, 2012. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommit tee/UCM303397.pdf. Accessed June 27, 2013.
21. Rockstroh JK, Lennox JL, Dejesus E, et al; STARTMRK Investigators. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53(8):807-816.
22. Bánhegyi D, Katlama C, da Cunha CA, et al. Week 96 effcacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN. Curr HIV Res. 2012;10(2):171-181.
23. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ ritonavir in patients with multiple virologic failures. AIDS. 2006;20(5): 711-718.
24. Anderson D, DeMasi R, DeLaitsch L, Surles T, Coate B. Week 96 outcomes of patients with less treatment experience versus more treatment experience receiving etravirine in the DUET trials. Curr HIV Res. 2012;10(3):256-261.
25. Hodder S, Jayaweera D, Mrus J, Ryan R, Witek J; Grace Study Group. Efficacy and safety outcomes among treatment-experienced women and men treated with extra virine in gender, race and clinical experience. AIDS Res Hum Retroviruses. 2012;28(6):544-551.
26. Clotet B, Bellos N, Molina JM, et al; POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369(9568):1169-1178.
27. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19(7):685-694.
28. Girard PM, Campbell T, Grinsztejn B, et al. Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest. HIV Med. 2012;13(7):427-435.
29. Stribild [Prescribing information]. Foster City, CA: Gilead Sciences Inc; 2012.
30. Antoniou T, Smith G, Su D, et al. Immunologic effectiveness of mara-viroc- and raltegravir-containing regimens (R+M+) versus raltegravir-based regimens that do not include maraviroc (R+M-). J Int Assoc Physicians AIDS Care (Chic). 2012;11(3):192-197.
31. Steigbigel RT, Cooper DA, Kumar PN, et al; BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359(4):339-354.
32. MAG Mutual Healthcare Solutions. Physicians' Fee and Coding Guide 2012. Atlanta, GA: MAG Mutual Healthcare Solutions; 2011.
33. Roskell NS, Shearer A, Gazzard B, et al. The impact of patient, disease, and treatment-related factors on quality of life for HIV patients on HAART. Abstract MOPE0656 presented at the XVI International AIDS Conference, August 13-18, 2006, Toronto, Ontario, Canada.
34. Sullivan P W, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006;26(4):410-420.